©2019 by HALO Diagnostics

Investigational Laser Focal Therapy (LITT or FLA) for Prostate Cancer

Once the tumor lesion has been detected and diagnosed, the final step in prostate cancer management is the treatment. Focal laser ablation (FLA) is an investigational procedure.

Learn more about focal laser ablation:

  • Focal laser ablation is a localized procedure available as an investigational therapy (ongoing clinical trial )

  • Real-time monitoring with MRI can allow targeting the laser probe to specific tumor lesions

  • Reduced chances of urinary incontinence 

  • Reduced risks of erectile dysfunction 

  • Same-day out-patient procedure

  • Quick recovery

  • Conscious sedation, no general anesthesia required 

  • Reduced pain and low risks of infection

  • Repeat procedures can be performed in the future

TALK TO A CLINICIAN!

Prostate Cancer Clinical Trial at DMI: 

The first case of focal laser ablation in the world was performed by Dr. John Feller, Dr. McNichols, and Ms. Greenwood on May 2010 as part of a Phase I Clinical Trial. 

In 2010 the team of Bernadette Greenwood, BSc, PG Cert., RT(R)(MR) and Roger J. McNichols, PhD developed a unique approach using the Visualase® Thermal Therapy System and the Invivo DynaCAD/DynaTRIM prostate biopsy system to perform Laser Interstitial Thermal Therapy (LITT) or Focal Laser Ablation (FLA) and began conducting an IRB-approved Clinical Trial, NCT 02243033. 

 

Find out if you are eligible for laser focal therapy (LITT or FLA) investigational trial

 

For “treatment-naive” patients (no prior therapy for prostate cancer)

  • If you are age 45 or older and have been diagnosed with low/ intermediate-risk prostate cancer confined to the prostate gland

  • Clinical stage T1c or T2

  • MR-guided biopsy confirmation of one or more MRI-visible prostate lesion(s) with a Gleason score of 7 (3+4 or 4+3) or less

  • Tolerance for anesthesia/sedation

  • Ability to give informed consent

  • At least 6 weeks since any previous prostate biopsy

Additional criteria can be discussed with our clinicians prior to enrollment

Individuals with recurrent prostate cancer may also consider enrollment under the referral of the treating physician

The current standard of care for aggressive prostate cancer is either the surgical radical removal of the prostate gland and/or whole gland radiation. 

Some common side effects with these procedures are:

  • Urinary incontinence in nearly 50% of men 

  • Erectile dysfunction and impotence 

  • Urinary tract infection

  • Potential injury to the rectum

  • Narrowing stricture of the urethra

Collectively these symptoms lead to a diminished quality of life post-surgery.

According to the U.S. Preventive Services Task Force’s statement in May 2018, “more harm than good was being done to men who underwent screening, biopsy and surgical removal of their prostate gland”. 

Participating in this study is completely voluntary

IF YOU ARE INTERESTED IN JOINING THIS STUDY, PLEASE CONTACT THE RESEARCH TEAM BELOW

TALK TO A CLINICIAN

IF YOU ARE INTERESTED IN JOINING THIS STUDY, PLEASE CONTACT THE RESEARCH TEAM 

NCT02243033

Principal Investigators:

John F. Feller, M.D.

Ms. Bernadette M. Greenwood,

BSc, PG Cert., RT (R) MR)


Data Manager/Research Coordinator:

Mari Mitchell

(760) 469-8111

Research Fax - 888-317-9823

prostate@desertmedicalimaging.com